John L. LaMattina

Board Member

Equibles does not estimate personal net worth.

Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.

Get LGND alerts

About John L. LaMattina

John L. LaMattina is recorded as Board Member at Ligand Pharmaceuticals Inc (LGND) since January 1, 2011. The newest filing on record that lists John L. LaMattina as Board Member at Ligand Pharmaceuticals Inc (LGND) is dated April 21, 2026. Earlier roles on record: Board Member at Immunome Inc. (IMNM) until October 2, 2023. Ligand Pharmaceuticals Inc reported in an 8-K filed June 17, 2024 that John L. LaMattina was appointed director. Immunome Inc. reported in an 8-K filed October 4, 2023 that John L. LaMattina resigned as Immunome's board of directors and any respective committee membership of Immunome's board of directors, effective October 2, 2023. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Tavo Espinoza (CFO), Jason Haas (Board Member) and 7 others.

“each nominee was elected to serve as a director of the Company.”

Ligand Pharmaceuticals Inc Form 8-K, filed June 17, 2024 · Read the filing

“(i) each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome's board of directors and any respective committee membership of Immunome's board of directors, effective as of the closing of the Merger”

Immunome Inc. Form 8-K, filed October 4, 2023 · Read the filing

Affiliation history

Ligand Pharmaceuticals Inc (LGND)
Board Member

Proxy statement

Current
2011-01-01–present

Last confirmed April 21, 2026
Immunome Inc. (IMNM)
Board Member

Proxy statement

2017-01-01–2023-10-02